By Mill Chart
Last update: Aug 14, 2023
Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if AMEDISYS INC (NASDAQ:AMED) is suited for quality investing. Investors should of couse do their own research, but we spotted AMEDISYS INC showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.
As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.
Overall AMED gets a fundamental rating of 5 out of 10. We evaluated AMED against 115 industry peers in the Health Care Providers & Services industry. AMED scores excellent on profitability, but there are some minor concerns on its financial health. AMED is valued correctly, but it does not seem to be growing.
Check the latest full fundamental report of AMED for a complete fundamental analysis.
More quality stocks can be found in our Caviar Cruise screen.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NASDAQ:AMED (11/29/2023, 7:00:00 PM)After market: 93.93 0 (0%)
These long-term care stocks provide older Americans with the care they need and the income to pay for it well into retirement.
Option Care Health's stock dropped 14% after the company revealed its preference for M&A deals rather than share repurchases in its Q3 results and...
BATON ROUGE, La., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month...
Held October 15-21, this Observance Shines a Light on Our Commitment to Quality Care...
Sen. Elizabeth Warren (D-MA) and Rep. Pramila Jayapal (D-WA) are asking antitrust regulators to look closely at UnitedHealth (UNH) planned $3.3 billion acquisition of Amedisys (AMED).
Two top progressive Democrats asked antitrust regulators to examine UnitedHealth Group Inc.’s planned $3.3 billion purchase of home-health provider Amedisys Inc. and challenge deals that bring medical providers under the same ownership as health insurers.
The best stock picks for this week have long-term aims such as high earnings and growth for your portfolio.
The Biden administration on Friday proposed standards requiring nationwide nursing homes to meet certain minimum staffing levels. Read the full story here.
BATON ROUGE, La., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the...